Stereotaxis, Inc.

AMEX:STXS

Medical - Instruments & Supplies

Healthcare
$0.95 +2.53%

+$0.05 today

Market cap
$94.80M
Beta
1.32
P/E (TTM)
-8.3
EPS (TTM)
-$0.22
52W Low $1.70High $3.59

Volume 0.90M

Average 0.39M

STXS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Stereotaxis, Inc.AMEX: STXS

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $3.52M (cash outflow) rose 97.9% year over year, ahead of the +94.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 12.8% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.

Context

  • Free cash flow amounted to 42.6% of revenue in FY2025, up 10.9 pp from a year earlier.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +97.9% holds above the trailing-twelve-month pace of +94.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.52M-12.8% QoQ
Last fiscal yearDec 2025
-$13.78M+61.5% YoY
LTMMar 2026
-$15.52M+94.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+97.9%——
1 year+61.5%——
3-year CAGR+8.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(13.78M) USD
Year-over-year change
-61.5%

Free Cash Flow vs competitors

How STXS compares with its peers on the latest reported figures

  • STXS's LTM Mar 2026 free cash flow of $15.52M is the 3rd largest of the 5 companies compared; the peer median is $16.49M.
  • Its year-over-year change of +94.9% is the 2nd highest of 5, against a peer median of +44.0%.
  • Free cash flow amounts to 49.8% of revenue for STXS, versus a peer median of 51.0%.
STXS Competitors Peer median
Free Cash Flow for STXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLPTClearPoint Neuro, Inc.LTM Mar 2026$26.7M +127.5%+14.2%65.8%
SSIISS Innovations International, Inc.LTM Mar 2026$17.59M +22.7%+149.1%36.3%
STXSStereotaxis, Inc.LTM Mar 2026$15.52M +94.9%+8.5%49.8%
MBOTMicrobot Medical Inc.LTM Mar 2026$15.38M +65.3%+4.1%14647.6%
NPCENeuroPace, Inc.LTM Mar 2026$9.84M -45.8%-32.9%9.9%
Peer median (excluding STXS) $16.49M+44.0%+9.1%51.0%

Competitors are the stored peer set for STXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Depreciation & Amortization106K429K595K969K1.56M
Deferred Income Tax00000
Stock-Based Compensation9.36M10.58M10.62M10.26M9.85M
Change in Working Capital135K(1.1M)612K2.51M(5.62M)
Accounts Receivables(1.89M)316K1.27M691K(2.02M)
Inventory(1.14M)(2.91M)(550K)677K(1.24M)
Accounts Payables1.43M(169K)218K758K(880K)
Other Working Capital1.73M1.66M(324K)379K(1.48M)
Other Non-Cash Items(1.83M)(25K)(256K)1.81M2.17M
Operating Cash Flow(2.95M)(8.42M)(9.14M)(8.5M)(13.69M)
Capital Expenditures(1.4M)(2.38M)(366K)(34K)(93K)
Acquisitions (Net)000108K0
Purchases of Investments0(19.72M)000
Sales of Investments0020.13M00
Other Investing Activities00000
Investing Cash Flow(1.4M)(22.09M)19.77M74K(93K)
Debt Repayment00000
Common Stock Issued547K220K81K297K14.76M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow547K220K81K297K14.76M
Effect of Forex Changes00000
Net Change in Cash(3.8M)(30.29M)10.71M(8.13M)985K
Free Cash Flow(4.34M)(10.79M)(9.51M)(8.53M)(13.78M)

Stereotaxis, Inc.

AMEX:STXS

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.